Navigation Links
Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
Date:4/8/2013

bone marrow. This is important because existing therapies often fail to effectively eliminate cancer cells in these tissue sites. Targeted therapy for CLL is becoming a reality, and this new approach may greatly improve the lives of patients with this disease."

The study also evaluated in vivo effects of ibrutinib using blood and tissue samples collected before and during treatment. Ibrutinib demonstrated rapid and sustained disease control in blood, lymph nodes, spleen and bone marrow. After 6 months, 95 percent of patients experienced a reduction in lymph node size and all showed reduction in spleen enlargement, with a median reduction of 55 percent. In 26 patients, for whom a bone marrow biopsy was done, tumor infiltration decreased by 82 percent.

The Progression Free Survival probability for these patients at 12 months was estimated to be 94 percent. Most adverse events were mild and manageable and included diarrhea, fatigue and rash, severe events occurred in less than 13 percent of patients. 

"We are very pleased with the continued research that is being demonstrated at AACR across 9 different presentations. These advances show the potential breadth of the ibrutinib program and provide further opportunities for us to pursue. We are grateful for the continued support of our collaborators, investigators, patients and shareholders," said Bob Duggan , CEO and chairman of the board.

Ibrutinib has been designated as a FDA Breakthrough Therapy in CLL patients with deletion 17p, based on data from completed Phase I/II clinical studies, where ibrutinib as a monotherapy was used to treat patients with this disease. Ibrutinib has the potential to improve the outcome in this serious and life-threatening disease, and may provide a substantial improvement over existing therapies for this indication.

About Chronic Lymphocytic Leukemia

CLL is the most common type of leukemia, a cancer of the whi
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... Massachusetts y LONDRES, August 29, 2015 /PRNewswire/ ... Inteligencia Anatómica para los sistemas de ... reproducibles en Ecografía, tiempos de examen rápidos y ... traduce en mayor confianza diagnóstica en el proceso de ...  (NYSE: PHG, AEX: PHIA) ha anunciado hoy el lanzamiento ...
(Date:8/28/2015)... India , August 28, 2015 ... Biomarker Market by Tumor (Breast, Lung, Prostate) Type (Protein ... Application (Diagnostic, Drug Discovery, Prognostic) & Geography - Global ... Market is expected to reach around 17,689.0 Million USD ... forecast period of 2015 to 2020. ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Tobramycin is a traditional antibiotic whose eye ... for the treatment of potential infection or inflammation caused ... China are able to produce tobramycin, ...
Breaking Medicine Technology:Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5Investigation Report on China's Tobramycin Market, 2015-2019 2
... Medical Care Technologies Inc. (OTCBB: MDCE), a children,s healthcare ... the Company,s common stock held on February 29, 2012 at ... adjourned Special Meeting will occur on March 29, 2012 at ... shareholders to ensure that their voting instructions are carried out ...
... 2012 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. ... of 1934 (Amendment No. 7)*REPLIGEN CORP (Name of Issuer)Common Stock, ... 10 9 (CUSIP Number) Barry L. Fischer Thompson ... 60603 (312) 346-75 (Name, Address and Telephone Number of Person ...
Cached Medicine Technology:Medical Care Technologies Inc. Announces Adjournment of Special Meeting 2Medical Care Technologies Inc. Announces Adjournment of Special Meeting 3Major Repligen (Nasdaq: RGEN) Shareholder Files Amended 13D 2Major Repligen (Nasdaq: RGEN) Shareholder Files Amended 13D 3Major Repligen (Nasdaq: RGEN) Shareholder Files Amended 13D 4Major Repligen (Nasdaq: RGEN) Shareholder Files Amended 13D 5
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at Estrella ... Colleges , will be hosting a Job Expo to provide a professional, open venue ... Expo has expanded to much more than just a typical job and career fair. ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the ... (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” , The ... PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., ...
(Date:8/29/2015)... ... August 29, 2015 , ... It ... and protection against dribbled urine and sweat. "In order to prevent these problems, ... The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a male’s ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., ... His mission is to increase acceptance of the chiropractic field in the military. All ... debilitate them. Although Chiropractic was made available to the VA program over a ...
(Date:8/29/2015)... ... August 29, 2015 , ... Next weekend is Labor Day weekend, ... officially ends on September 22nd this year). For IT security personnel, it should also ... which could prove far more costly than a simple headache. , Joe Caruso, founder ...
Breaking Medicine News(10 mins):Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
... Pharmaceuticals, Inc., an,innovative biotechnology company focusing on ... that it has appointed Linda Hogan as ... Hogan will apply more,than 25 years of ... drive CoLucid,s business development strategies. She will,lead ...
... Conn., Oct. 28 This November, Philips Norelco,will ... awareness,for prostate cancer, a disease that affects one ... as November, has emerged as an annual,global ",Mo,-vement" ... sole,beneficiary of these funds in the U.S. is ...
... device and finance ... background., ... point-of-care robotic systems for the fabrication and,tracking of customized, nano-material-based wound ... officer. Coughlen,joined the PolyRemedy management team on October 14, 2008, and ...
... eSolution" to clinical ... ... software company,focused on developing web-based integrated clinical trials management,systems (CTMS), ... contract research organization (CRO) and ECG core,lab Spacelabs Healthcare Clinical ...
... 28 /Xinhua-PRNewswire-FirstCall/ -- Golden Meditech,Company Limited ("Golden Meditech" ... today that the Group has increased shareholding in ... listed on,Australia Stock Exchange, to 18.9%, and became ... 2.4 million Australian Dollars,(equivalent to HK$12 million)., ...
... Brain Injury Association (CALBIA), a non-profit membership ... those affected by brain injury, together with the ... representing individuals sustaining traumatic brain injury , ... nation’s most important professional medical/legal conferences dealing with ...
Cached Medicine News:Health News:CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development 2Health News:CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development 3Health News:Philips Norelco Encourages Americans to Change the Face of Men's Health: Grow a Moustache This November and Raise Awareness for Prostate Cancer Research 2Health News:Philips Norelco Encourages Americans to Change the Face of Men's Health: Grow a Moustache This November and Raise Awareness for Prostate Cancer Research 3Health News:Philips Norelco Encourages Americans to Change the Face of Men's Health: Grow a Moustache This November and Raise Awareness for Prostate Cancer Research 4Health News:PolyRemedy Hires Gary Coughlen as CFO 2Health News:ECRFPlus Achieves Milestone Multimillion Dollar Enterprise Agreement With CRO and Launches e-CRF+(TM): a CTMS and EDC Web Platform With ECG Analysis and Cardiac Safety Module. 2Health News:ECRFPlus Achieves Milestone Multimillion Dollar Enterprise Agreement With CRO and Launches e-CRF+(TM): a CTMS and EDC Web Platform With ECG Analysis and Cardiac Safety Module. 3Health News:ECRFPlus Achieves Milestone Multimillion Dollar Enterprise Agreement With CRO and Launches e-CRF+(TM): a CTMS and EDC Web Platform With ECG Analysis and Cardiac Safety Module. 4Health News:Golden Meditech Increases Stakes in Cordlife, Largest Cord Blood Bank Operator in Southeast Asia 2Health News:California Brain Injury Association and Scarlett Law Group Conduct Medical/Legal Conference on Traumatic Brain Injury November 21 - 23rd, 2008 2Health News:California Brain Injury Association and Scarlett Law Group Conduct Medical/Legal Conference on Traumatic Brain Injury November 21 - 23rd, 2008 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: